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a  b  s  t  r  a  c  t
Introduction: Allogeneic hematopoietic stem cell transplantation offers the opportunity for
extended survival in patients with Hodgkin’s and non-Hodgkin lymphomas who relapsed
after, or were deemed ineligible for, autologous transplantation. This study reports the
cumulative experience of a single center over the past 14 years aiming to deﬁne the impact
of  patient, disease, and transplant-related characteristics on outcomes.
Methods: All patients with histologically conﬁrmed diagnosis of Hodgkin’s or non-Hodgkin
lymphomas who received allogeneic transplantation from 2000 to 2014 were retrospectively
studied.
Results: Forty-one patients were reviewed: 10 (24%) had Hodgkin’s and 31 (76%) had non-
Hodgkin lymphomas. The median age was 50 years and 23 (56%) were male. The majority of
patients (68%) had had a prior autologous transplantation. At the time of allogeneic trans-
plantation, 18 (43%) patients were in complete and seven (17%) were in partial remission.
Most  (95%) patients received reduced-intensity conditioning, 49% received matched sibling
donor grafts, 24% matched-unrelated donor grafts, and 27% received double umbilical cord
blood  grafts. The 100-day treatment-related mortality rate was 12%. After a median duration
of  follow up of 17.1 months, the median progression-free and overall survival was 40.5 and
95.8  months, respectively. On multivariate analysis, patients who had active disease at the
time of transplant had inferior survival.
Conclusions: Allogeneic transplantation results extend survival in selected patients with
relapsed/refractory Hodgkin’s and non-Hodgkin lymphomas with low treatment-related
mortality. Patients who have active disease at the time of allogeneic transplantation have
poor  outcomes.© 2016 Associac¸a˜o Bra
by  Elsevier Editora Lt
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ntroduction
odgkin’s and non-Hodgkin lymphoma (HL and NHL) are
 heterogeneous group of hematologic malignancies with
aried aggressiveness and many  therapeutic options. An esti-
ated 66,360 new cases of NHL were diagnosed in the United
tates in 2011. B-cell non-Hodgkin (B-NHL) lymphomas com-
rise approximately 85% of these cases. Transplantation, both
utologous and allogeneic, has a role in the management of
-cell lymphoma, with more  than 5000 hematopoietic cell
ransplantations (HCTs) being performed annually in North
merica for this indication. Diffuse large B-cell lymphoma
DLBCL) is the most common type of lymphoma seen in devel-
ped countries, accounting for 30% of all newly diagnosed
HL. It is an aggressive lymphoma, and when treated with
nthracycline and rituximab-based chemotherapy, only half
f the patients are cured with upfront therapy.1
High-dose therapy followed by autologous stem cell trans-
lantation (autoSCT) has been the standard care for patients
ith relapsed B-NHL. The efﬁcacy of autoSCT as salvage
or such patients, in the post-rituximab era, was recently
uestioned by the Collaborative Trial in Relapsed Aggres-
ive Lymphoma (CORAL) which demonstrated a dismal 23%
rogression-free survival (PFS) at two years.2 Historically, allo-
eneic transplantation (alloSCT) was considered an option
fter failure of autoSCT but some centers have transplanted
igher risk B-NHL cases at ﬁrst relapse or second com-
lete remission. No prospective comparative studies have
een completed in this setting.1 The effectiveness of alloSCT
n B-NHL has been attributed to a graft-versus-leukemia
GVL) effect because of the elimination of tumor cells by
lloimmune effector lymphocytes. Durable responses were
emonstrated after alloSCT in follicular lymphomas (FL) how-
ver a higher transplant-related mortality (TRM) related to
yeloablative conditioning regimens limited the widespread
se of alloSCT for FL.1 Earlier studies, including a large analysis
rom the Center for International Blood and Marrow Trans-
lant Research (CIBMTR),3 demonstrated a differential GVL
ffect among B-NHL patients with low/intermediate grade
istologies, such as FL and mantle cell lymphoma (MCL),
eing more  sensitive to GVL compared to their aggressive
ounterparts (DLBCL and Burkitt’s lymphoma). The advent of
educed-intensity conditioning (RIC) regimens has renewed
nterest in alloSCT, which reduces TRM while maintaining
 GVL effect and therefore allows the treatment of elderly
atients and patients with comorbidities.4 A more  recent anal-
sis from the CIBMTR has shown that disease status was the
ain determining factor for outcomes after alloSCT regard-
ess of the intensity of conditioning regimen in DLBCL.5 Given
he limited efﬁcacy of autoSCT in the post-rituximab era
nd the decreased TRM with RIC, it is likely that the use
f alloSCT in B-NHL will expand. Further understanding of
he factors likely to predict a more  robust GVL response,
nd potentially better clinical outcomes, will be very useful
n selecting patients with B-NHL who are likely to beneﬁt
rom alloSCT. T-cell NHL accounts for only 30% of all NHL
nd represents a highly heterogeneous group where the role
f alloSCT remains undeﬁned.6 AlloSCT is usually offered to
atients with HL as a salvage therapy following relapse or 1 6;3  8(4):314–319 315
progression after autoSCT. Failure of autoSCT may be salvaged
by alloSCT with extended survival in highly selected patient
populations.7
This study reports the cumulative experience of one single
center aiming to deﬁne the impact of patient, disease, and
transplant-related characteristics on outcomes.
Methods
The transplant database of the University Hospitals Case Med-
ical Center (UHCMC) was searched to identify patients with
HL and NHL who received alloSCT from 2000 to 2014. All
patients included in the analysis had a centrally-conﬁrmed
histologic diagnosis of HL or NHL. The study was approved
by the UHCMC institutional review board. All patients had a
comprehensive evaluation before alloSCT to ensure that they
had adequate cardiac, pulmonary, renal, and hepatic func-
tions per institution protocol. All patients included in the
analysis received either mobilized peripheral blood stem cells
(PBSC) or double umbilical cord blood (dUCB) grafts. All of the
transplantations were performed on an inpatient basis and
patients received care in private rooms with laminar airﬂow.
PBSC grafts were either from a matched sibling donor (MRD)
or human leukocyte antigen (HLA) 7/8 or 8/8 matched (to HLA
A, B, C, DR, and DQ loci) unrelated donor (MUD). UCB as a
graft source was only considered in the absence of an adult
HLA-matched related or unrelated donor. For dUCB grafts,
a minimum of 1.5 × 107 total nucleated cells/kg of recipient
body weight cell dose was required. Also dUCB units had to
be matched for at least three HLA loci (A, B, DRB1) between
each other and to the recipient. Most transplants employed
RIC with ﬂudarabine and cyclophosphamide (FluCy) with or
without rabbit antithymocyte globulin (ATG). Most patients
who received dUCB grafts were also conditioned with 200 cGy
of total body irradiation (TBI). All patients received graft vs.
host disease (GVHD) prophylaxis with a calcenurin inhibitor
(cyclosporine A or tacrolimus) with or without reduced-dose
methotrexate (5–15 mg/m2) on Days +1, +3, +6, +11 after trans-
plant or mycophenolate mofetil (for 30 days after transplant).
Most patients received growth factor support, supportive
transfusions, and prophylactic antimicrobial agents per insti-
tutional protocol. Calcenurin inhibitors (CI) were tapered
from 120 days after transplant with most patients being
tapered off CIs by six months in the absence of active
GVHD.
Deﬁnitions
For disease status at the time of transplantation, a complete
response (CR) was deﬁned as the absence of all clinical and
radiographic evidence of disease at the time of transplantation
after upfront chemotherapy or salvage chemotherapy after
ﬁrst or subsequent relapse(s). A partial response was deﬁned
as >50% reduction of the surface area of all measurable dis-
ease in response to the salvage chemotherapy given before
transplantation. Some patients received transplantation in
ﬁrst or subsequent relapses without a prior autoSCT; these
patients either had a lymphoma with a high risk of relapse
after autoSCT (usually due to failure to attain a CR after salvage
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Table 1 – Patient characteristics.
Patient characteristic
Age – Median (Range), years 50 (45–55)
Male gender – n (%) 23 (56)
Histology – n (%)
Hodgkin’s lymphoma 10 (24)
Non-Hodgkin lymphoma 31 (76)
Diffuse large B-cell lymphoma 9 (22)
Follicular lymphoma 9 (22)
Mantle cell lymphoma 6 (15)
T-cell lymphoma 2 (4)
Others 5 (12)
Disease status at alloSCT – n (%)
Complete remission 18 (43)
Partial remission 7 (17)
Stable disease 8 (19)
Progressive (active) disease 8 (19)
Ann Arbor Staging at presentation – n (%)
Early stage (I/II) 6 (15)
Advanced stage (III/IV) 35 (85)
Extranodal disease at presentation – n (%) 6 (15)
Prior autoSCT – n (%) 24 (58)
Interval from diagnosis to alloSCT ≥ 1 year 39 (95)
HCT-CI – median (range) 0 (0–3)
alloSCT: allogeneic stem cell transplantation; autoSCT: autol-



















































Figure 1 – Progression-free (A) and overall survival (OS) after
allogeneic transplantation (with 95% conﬁdence intervals).transplantation-speciﬁc comorbidity index.
chemotherapy) or had a high-risk FL with an HLA-identical
sibling donor available. Acute GVHD was graded based on
the International Bone Marrow Transplant Registry (IBMTR)
Severity Index8; grades C/D were categorized as “severe acute
Table 2 – Allogeneic transplant characteristics.
Transplant characteristic
Donor type – n (%)
Sibling donor 20 (49)
Matched unrelated donor 10 (24)
Umbilical cord blood 11 (27)
Conditioning regimen






Anti-thymocyte globulin – n (%) 27 (77)
CD34+ cell dose (×106) – median (95%
conﬁdence interval)
6.2  (5.26–6.67)
GVHD prophylaxis – n (%)
Cyclosporine ± methotrexate or MMF 37 (90)
Tacrolimus/methotrexate 4 (10)
Severe acute GVHD – n (%) 10 (24)
Moderate/severe chronic GVHD – n (%) 8 (20)
±: with or without; TBI: total body irradiation; GVHD: graft vs. host
disease; MMF: mycophenolate mofetil.GVHD” for the purpose of this analysis. Chronic GVHD was
graded according to the National Institute of Health (NIH) 2015
consensus criteria.9 To maintain consistency in GVHD grading,
many  cases were graded retrospectively. The hematopoi-
etic cell transplantation-speciﬁc comorbidity index (HCT-CI)
was calculated pre-transplant as described previously.10
TRM was deﬁned as the cumulative incidence of death
within 100 days after alloSCT without evidence of disease
progression.
Statistical  analysis
Overall survival (OS) was measured from the date of trans-
plant to the date of death and with censoring at the date of
last follow-up for survivors. Progression free survival (PFS) was
measured from the date of transplant to the date of disease
progression or the date of death, whichever occurred earlier,
and with censoring at the date of last follow-up for those
alive without progression. Survivor distribution was estimated
using the Kaplan–Meier method11 and difference of OS and
PFS between/among groups was examined by log-rank. The
effect of continuous variables on survival (OS, PFS) was esti-
mated using the Cox model.12 Factors signiﬁcant at univariate
analysis were further evaluated using a multivariable Cox
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atient  characteristics
orty-one alloSCTs were performed between 2000 and 2014:
0 (24%) for HL and 31 (76%) for NHL. The median age was
0 years (range: 16–69 years) and 23 (56%) patients were male.
he majority of patients (58%) had undergone a prior autoSCT.
t the time of alloSCT, 18 (43%) patients were in CR and seven
17%) were in PR. The median HCT-CI was 0 (range: 0–3). Patient
haracteristics are summarized in Table 1.
ransplant  procedure
ransplant characteristics are shown in Table 2. The sources
or hematopoietic stem cells were HLA-matched sibling
onors (49%), double umbilical cord blood (27%) and matched-
nrelated donors (24%). Most patients (95%) received reduced
ntensity conditioning prior to alloSCT with the commonest


























































































igure 2 – Impact of disease and transplant-related factors on pr
llogeneic transplant; remission status prior to transplant (A, B), 
C, D), graft source; matched-related donor (MRD) vs. matched-un
nd F). 1 6;3  8(4):314–319 317
(83%). The median CD34+ cell dose was 6.2 × 106/kg. All
patients, but one, engrafted neutrophils. Most patients (90%)
received cyclosporine A-based regimens for GVHD prophy-
laxis. The incidence of severe aGVHD (Grade C/D) was  24% and
moderate/severe cGVHD was 20%.
Survival
Median follow-up was 17.1 months (range: 0.8–130.7 months).
Median OS was 95.8 months and the one-year OS was 77.3%
(Figure 1A). Median PFS was 40.5 months and the one-year
PFS was 62.8% (Figure 1B). Five patients died within 100 days of
alloSCT giving a TRM rate of 12%. By multivariate analysis, only
remission status prior to alloSCT was signiﬁcant for inferior
outcomes (Figure 2A and B). The hazard of death was reduced
by 95% in patients who had achieved complete or partial
remission (CR/PR) compared to those who had active disease
prior to alloSCT (p-value = 0.001). Age at alloSCT, gender, sub-
type of lymphoma (Hodgkin’s vs. non-Hodgkin), HCT-CI and
graft source were not associated with outcomes in the Cox-













































































ogression-free (PFS) and overall survival (OS) after
lymphoma subtype; Hodgkin’s vs. non-Hodgkin lymphoma
related donor (MUD) vs. umbilical cord blood (UCB) grafts (E
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Discussion
This study conﬁrms that long-term survival is achievable
after alloSCT in patients with lymphomas. As with most
retrospective studies in patients submitted to alloSCT, the
heterogeneity in relation to disease entities, remission sta-
tus, transplant center choice of conditioning regimens, graft
source, method of GVHD prophylaxis, and supportive care
practices make any direct comparisons challenging. With
most patients in the current cohort receiving RIC, the out-
comes of alloSCT were favorable with 77% and 44% of patients
alive at one and ten years after transplantation. This is despite
the fact that less than half of the patients were in CR at the
time of transplantation. The results here compare favorably
with patients receiving RIC alloSCT as reported in recent reg-
istry studies from the CIBMTR with one-year survival rates of
41%, 56%, and 77% in patients who  had DLBCL, HL, and FL,
respectively.5,13,14 The 100-day TRM rate of this study was 12%
which compares favorably with some reports (25%, 15% and
13%).5,13,14
The results in this study suggest similar outcomes with
dUCB grafts compared to fully matched adult donors. Limited
data have been published on the role of dUCB alloSCT in
patients with lymphoma. A study from Eurocord-Netcord of
104 adult patients with lymphoid malignancies who received
UCB alloSCT reported one-year PFS and OS of 40% and 48%,
respectively although only 25% of patients received dUCB
units and 48% received low-dose TBI. The use of low-dose
TBI in that report was associated with lower risk of engraft-
ment failure.15 A more  recent study of 27 patients who
received dUCB alloSCT for relapsed/refractory HL at two cen-
ters reported a 26% TRM at 100 days with two-year PFS and
OS of 41% and 56%, respectively.16 In this study, 5/11 dUCB
transplants (45%) had relapsed/refractory HL. The PFS and OS
for the 11 transplants were 42% and 48%, respectively at two
years, which is comparable. In this same series, the two-year
PFS and OS for the entire lymphoma cohort were 52% and
62% and 40% and 35% for MRD  and MUD  grafts, respectively,
suggesting comparable outcomes for adult donors (Figure 2E
and F).
Historically, aggressive lymphomas were considered to
be less sensitive to the immunologic GVL effect and hence
patients would beneﬁt less from alloSCT.17 Differences in
intrinsic antigen-presenting abilities of aggressive lymphoma
in contrast to indolent lymphomas were proposed however
it is likely that the more  aggressive gross kinetics of aggres-
sive lymphomas outpace an effective GVL.18 In this study,
the only factor that was highly signiﬁcant in inﬂuencing out-
comes after alloSCT was remission status. A recent CIBMTR
analysis of 533 patients with DLBCL and Grade 3 FL showed
no improvement in the PFS or OS with the use of myeloabla-
tive compared to RIC conditioning regimens.5 Another CIBMR
analysis of 336 patients with NHL (with >50% of patients
with FL or MCL) showed that pre-alloSCT positron emission
tomography (PET) positivity and not disease histology was
associated with increased risk of relapse/progression.19 The
results of this study conﬁrm that disease control, rather than
histology, is the main determining factor in outcomes after
alloSCT.
1 2 0 1 6;3  8(4):314–319
Conclusions
Allogeneic transplants are associated with extended disease
control in patients with relapsed and refractory HL and NHL
and low mortality in selected patients. Adequate disease con-
trol prior to proceeding to alloSCT is of paramount importance.
dUCB grafts remain a good option for patients who  do not have
an available adult donor with the outcomes being favorable in
centers with adequate experience in dUCB transplantation.
The potential role of haploidentical transplants in this setting
is intriguing and is currently under investigation.20
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